Jardiance 10 mg film-coated tablets clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic use (Phase IV)
Reducing Non-Alcoholic Steatohepatitis
This study is looking at how a medicine called Jardiance might help people with a liver condition called non-alcoholic steatohepatitis (NASH). Researchers want to see if it can improve liver health and reduce liver scarring, which is common in NASH.
For: Metabolic dysfunction-associated steatohepatitisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study)
This study looks at how a medicine called Empagliflozin might help people with early heart weakening by checking changes in a heart chamber. It also explores using Fitbits to help people exercise more, aiming to improve heart health before full heart failure develops.
For: Pre-Heart Failure (Non-diabetic)Ireland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia.
This study is looking at a medicine called empagliflozin (Jardiance) to see if it's safe and helpful for adults with a very rare condition called Glycogenosis type Ib. We want to find out if it can improve their low neutrophil count, which is a type of white blood cell.
For: Glycogenosis type Ib is an ultra-rare disease, inherited in an autosomal recessive manner.Poland